PMC:13914 / 1627-2465 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/13914","sourcedb":"PMC","sourceid":"13914","source_url":"http://www.ncbi.nlm.nih.gov/pmc/13914","text":"Results:\nOf 92 patients, 57.6% (n = 53) were classified as heritably GSTM1-deficient, and 42.4% (n = 39) were of the GSTM1-positive genotype. There were no statistically significant relationships between GSTM1-null genotype and the clinicopathological parameters analysed. No relationship was observed between GSTM1 RNA expression and objective clinical response to chemotherapy. Objective clinical response to chemotherapy was related only to clinical tumour size (P = 0.0177) and to the absence of intraductal carcinoma (P = 0.0013). GSTM1-null genotype had no effect on disease-free or overall survival. The absence of hormone receptors (P = 0.002), the presence of a mutated p53 gene (P = 0.0098) and lack of response to primary chemotherapy (P = 0.0086) were the only factors associated with reduced disease-free or overall survival.","divisions":[{"label":"Title","span":{"begin":0,"end":8}}],"tracks":[]}